Abstract
Secreted aspartic proteinases (Saps) are important virulence factors in different types of candidiasis caused by Candida albicans (C. albicans). The various isoenzymes are expected to fulfil different tasks during mucosal or disseminated infections. It could be shown that the introduction of the proteinase inhibitors like saquinavir and indinavir in the therapy of human immunodeficiency virus (HIV) infected patients has an effect on Sap activity in vitro as well as in vivo. Therefore, drugs like the HIV proteinase inhibitors could play an essential role in the treatment of candidiasis in the future, especially if further adapted to this target.
Current Drug Targets
Title: The Secreted Aspartic Proteinases as a New Target in the Therapy of Candidiasis
Volume: 3 Issue: 5
Author(s): M. Bein, M. Schaller and H.C. Korting
Affiliation:
Abstract: Secreted aspartic proteinases (Saps) are important virulence factors in different types of candidiasis caused by Candida albicans (C. albicans). The various isoenzymes are expected to fulfil different tasks during mucosal or disseminated infections. It could be shown that the introduction of the proteinase inhibitors like saquinavir and indinavir in the therapy of human immunodeficiency virus (HIV) infected patients has an effect on Sap activity in vitro as well as in vivo. Therefore, drugs like the HIV proteinase inhibitors could play an essential role in the treatment of candidiasis in the future, especially if further adapted to this target.
Export Options
About this article
Cite this article as:
M. Bein , M. Schaller and H.C. Korting , The Secreted Aspartic Proteinases as a New Target in the Therapy of Candidiasis, Current Drug Targets 2002; 3 (5) . https://dx.doi.org/10.2174/1389450023347542
DOI https://dx.doi.org/10.2174/1389450023347542 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Clinical Review on Nutritional Requirements and Assessment for Type 2 Diabetes Mellitus with Chronic Renal Disease
Current Diabetes Reviews Clinical Consequences and Novel Therapy of Hyperphosphatemia: Lanthanum Carbonate for Dialysis Patients
Recent Patents on Cardiovascular Drug Discovery Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry Choice of Antihypertensive Treatment in Subjects with Pre-Diabetes. Is There a Dream After the Navigator
Current Vascular Pharmacology Depression Under the Perspective of Oxytocin
Central Nervous System Agents in Medicinal Chemistry Passive Smoking, Endothelial Dysfunction and Related Markers in Healthy Individuals: An Update
Current Hypertension Reviews Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design An Integrated Computational Approach for Plant-Based Protein Tyrosine Phosphatase Non-Receptor Type 1 Inhibitors
Current Computer-Aided Drug Design Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets Mechanisms of Vascular Calcification and Associated Diseases
Current Pharmaceutical Design Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Atenolol: Differences in Mode of Action Compared with other Antihypertensives.An Opportunity to Identify Features that Influence Outcome?
Current Pharmaceutical Design Insulin Secretion and Interleukin-1β Dependent Mechanisms in Human Diabetes Remission After Metabolic Surgery
Current Medicinal Chemistry Targeting Redox Signaling in the Vascular Wall: From Basic Science to Clinical Practice
Current Pharmaceutical Design The Role of Coronary Collaterals in Chronic Total Occlusions
Current Cardiology Reviews The Hot and Potential Targets of Type 2 Diabetes Mellitus Treatment in Recent Decade
Current Drug Targets Vitamin E - Occurrence, Biosynthesis by Plants and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Modifiers of Liver-Related Manifestation in the Course of NAFLD
Current Pharmaceutical Design Diabetes-Related Neurological Implications and Pharmacogenomics
Current Pharmaceutical Design